Automated Lab Platform for Life Sciences
Transforming healthcare, biopharma, and R&D
Who we are

Biology holds the solution to humanity’s grand challenges

At present, the development of those solutions is hindered by slow, expensive, and overly complex lab workflows.

We are dedicated to developing a platform that integrates robotics, software, assay development, and lab operations to supercharge the pace of innovation in life sciences.

What we do

We build state-of-the-art labs from the ground up with custom automation, software, and assays.

We supply lab services to healthcare systems, offering affordable, high-throughput solutions for molecular diagnostics.

We offer genome-scale cell engineering solutions for biopharma, enabling the development of novel therapeutics.

We create flexible, easy-to-use robotics to help life science labs in academia and industry automate their operations.

Our business
Opentrons Robotics
Opentrons Robotics
Opentrons Robotics is the industry leader in flexible, user-friendly lab automation. Opentrons Robotics' flagship product, the OT-2, can be found in thousands of labs in more than 40 countries.
Pandemic Response Lab
Pandemic Response Lab
Pandemic Response Lab (PRL) uses the Opentrons’ platform to provide diagnostic lab services to health systems across the US.
Neochromosome
Neochromosome
Neochromosome uses the Opentrons platform to create genome-scale cell engineering solutions for therapeutics.
Zenith AI
Zenith AI
Zenith AI brings proprietary no-code AI and modern machine learning to the Opentrons platform.
Our leadership
Executive team
  • Photo of John Badal
    John Badal
    CEO, Opentrons Labworks, Inc.
  • Photo of Eva Boratto
    Eva Boratto
    CFO, Opentrons Labworks, Inc
  • Photo of Veleka Peeples-Dyer
    Veleka Peeples-Dyer
    Chief Legal Officer, Corporate Secretary and Chief Compliance Officer, Opentrons Labworks, Inc
Leadership
  • Photo of David Kim
    David Kim
    GM, Opentrons Robotics
  • Photo of Neil Robertson
    Neil Robertson
    CEO, ZenithAI
  • Photo of Leslie Mitchell
    Leslie Mitchell
    CEO, Neochromosome, Inc
Board and Advisors
  • Photo of Myrtle Potter
    Myrtle Potter
    Chair of the Board, Opentrons Labworks, Inc
  • Photo of Robert S. Langer
    Robert S. Langer
    Head of Scientific Advisory Board, Neochromosome, Inc
  • Photo of Jef Boeke
    Jef Boeke
    Head of Scientific Advisory Board, PRL
  • Photo of Greg Greeley
    Greg Greeley
    Advisor, Opentrons Labworks, Inc
  • Photo of Angela Du
    Angela Du
    Member of the Board, Opentrons Labworks, Inc
  • Photo of Eric Hippeau
    Eric Hippeau
    Member of the Board, Opentrons Labworks, Inc
  • Photo of Sven Strohband
    Sven Strohband
    Member of the Board, Opentrons Labworks, Inc
48
Countries
5,000+
Happy Customers
5M+
Diagnostic Tests
$250M+
Funds Raised
500
Team Members
Our Investors
  • investor logo
  • investor logo
  • investor logo
  • investor logo
  • investor logo
  • investor logo
Opentrons announces $200 million series C led by Softbank
Opentrons will use this funding to scale its automated lab platform for life sciences and healthcare.
Read more →
https://www.cigna.com/legal/compliance/machine-readable-files

This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.

facebook
instagram
twitter
youtube
© 2022 Opentrons Labworks